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Abstract Thyroid hormones are known to stimulate ther-
mogenesis in rodents by exerting a permissive effect on
norepinephrine that affects uncoupling protein-1 (UCP1)
expression in brown adipose tissue (BAT). The aim of this
study was to identify new targets of the thermogenic effects
of T3 in tissues other than the BAT, such as skeletal muscle.
In b1/b2/b3-adrenoceptor knockout (b-less) mice, that are
dramatically cold intolerant, a normal body temperature was
maintained throughout 48 h of cold exposure by T3 admin-
istration. In these mice, BAT UCP1 protein expression was
not modified either by cold exposure or by T3 administration.
To test the possibility that T3 might act via muscle uncou-
pling protein-3 (UCP3), an UCP3 knockout (KO) model was
used. This model exhibited a normal phenotype except that,
upon T3 administration, stimulated oxygen consumption of
the UCP3KO mice was significantly lower by 6% than that of
the wild-type (WT) mice. This difference was observed only
during the dark period (between 7.00 p.m. and 7.00 a.m.),
i.e. when the mice are the most active at consuming food.
Therefore, UCP3 might participate in the correction by T3 of
the dramatic cold intolerance of the b-less mice. These
results reactivate the idea that UCP3 might play a role in the
control of energy balance.
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Introduction
Rodent brown adipose tissue (BAT), because it contains a
unique mitochondrial uncoupling protein, termed uncou-
pling protein-1 (UCP1), is considered the main effector of
adaptive thermogenesis. Cold exposure, via a stimulation
of the BAT sympathetic nervous system activity, increases
mitochondriogenesis, UCP1 expression and activity as well
as the size and number of brown adipocytes resulting in a
phenomenon known as cold-induced thermogenesis [1, 2].
Studies on hypothyroid rodents have shown that the
active form of thyroid hormones, 3,5,30-triiodothyronine
(T3), exerts a permissive role on norepinephrine effect in
the BAT and is therefore necessary for a full thermogenic
response to cold exposure [3, 4]. The conversion of
3,5,30,50-tetraiodothyronine (T4) to T3 by type II 50-deio-
dinase (D2) is the unique source of intracellular T3 in the
BAT. The a- and b1/b2/b3-adrenoceptors, stimulated by the
sympathetic nervous system, act in a synergistic fashion
to stimulate the mRNA expression and the activity of D2
[5–7]. Therefore, optimal UCP1 response to the cold
requires a conversion of T4 to T3 in the BAT [5, 8, 9].
b1/b2/b3-adrenoceptor knockout (b-less) mice have been
created which were found to exhibit a normophagic obesity
and a dramatic cold intolerance [10, 11]. BAT from these
animals showed a total inhibition of the cold-induced
Pierre Flandin and Lorenz Lehr have contributed equally to this work.
P. Flandin  L. Lehr  C. Asensio  P. Muzzin
Department of Cell Physiology and Metabolism, Medical
University Centre, Geneva, Switzerland
J.-P. Giacobino (&)  M. Jimenez
Department of Medical Biochemistry, Medical University
Centre, Geneva, Switzerland
e-mail: jean-paul.giacobino@unige.ch
Present Address:
J.-P. Giacobino
16 rue Jean-Se´nebier, 1205 Geneva, Switzerland
F. Rohner-Jeanrenaud
Department of Internal Medicine, Division of Endocrinology,
Diabetology and Nutrition, Medical University Centre,
Geneva, Switzerland
Endocr (2009) 36:246–254
DOI 10.1007/s12020-009-9217-8
induction of UCP1 protein expression [10, 11] and of D2
activity [11]. The latter observation suggested that the BAT
of the b-less mice should not be able to respond to thyroid
hormones.
The uncoupling protein-3 (UCP3) owes its name to its
close sequence homology with the canonical UCP1. UCP3
expression is restricted to the skeletal muscle and the brown
fat in the rodents and it was believed that it could play an
important role in energy balance [12]. UCP3 knockout (KO)
mice have been generated [13–16]. The mitochondria of
their skeletal muscle displayed increased coupling of res-
piration to ADP availability (State 3/State 4 ratio) [14] and
decreased proton leak [13, 15] as compared to those of the
wild-type (WT) mice. Despite this uncoupling of oxidative
phosphorylation in their muscle, the UCP3KO mice did not
display phenotypic abnormalities of their energy balance. In
particular, their body weights, both on a chow or a high fat
diet, their exercise tolerance and their cold-induced ther-
mogenesis were normal [13, 14]. The only exception was
the observation that a long-term high fat diet induced a
higher accumulation of intramuscular triglycerides in
UCP3KO than in WT mice [16]. Mice with an overex-
pression of UCP3 protein in their skeletal muscle (UCP3-tg)
generated by several laboratories [17–20] were all found to
be obesity resistant. The UCP3-tg mice of Tiraby et al. [19]
in which UCP3 overexpression was of moderate amplitude
and restricted to the muscle glycolytic fibres revealed an
uncoupling of oxidative phosphorylation and sex-specific
changes in insulin sensitivity. The UCP3-tg models suggest
that UCP3 should still be considered as a potential player in
the control of energy balance.
There are striking data in the literature showing the
privileged relationship between UCP3 thermogenic activity
and thyroid hormones. T3 treatment, which increased
UCP3 expression in skeletal muscle, induced a decrease in
mitochondrial energy coupling in vivo in this tissue [21].
Furthermore, a study on hypothyroid rats given a single
injection of T3 demonstrated an increase in UCP3
expression paralleled by an uncoupling of isolated mito-
chondria oxidative phosphorylation in skeletal muscle as
well as an increase in the resting metabolic rate. The three
responses were strictly correlated in terms of time course
[22]. Finally, it has recently been shown that the increase in
body temperature induced by the amphetamine-type stim-
ulant ecstasy is strongly decreased in UCP3KO mice,
suggesting that UCP3 is the molecular mediator of this
response [23]. Furthermore, it has been shown that thyroid
hormones can modulate the induction by amphetamine-like
drugs of UCP3-dependent thermogenesis [24, 25].
The aim of this study was to test the hypothesis that
skeletal muscle UCP3 is a molecular determinant of the
effect of T3 on energy balance. For that purpose, two
models of transgenic mice generated in our laboratory were
used. First, the b-less mice [10] which allowed, in the
absence of a BAT reactivity, to study a possible effect of
T3 on thermogenesis and second, UCP3KO mice which
allowed to quantify the part played by UCP3 in the effect
of T3 on oxygen consumption.
Results
b-less mice
We have previously shown that the basal colonic temper-
ature of our b-less mice was 1.2C lower than that of the
WT mice. During the first 24 h of a cold exposure (6C),
the colonic temperature of 10 out of 13 b-less mice fell
below 34C, and after 48 h of cold exposure, only 3 out of
the 13 b-less mice survived, exhibiting a colonic temper-
ature about 4C lower than that of the WT mice [10]. In
this study, the possible effect of T3 on the b-less mouse
cold intolerance was tested. WT and b-less mice were
treated with an intraperitoneal injection of T3 (0.5 lg/g of
body weight) immediately before cold exposure and then
three times at intervals of 12 h. Surprisingly, b-less mice
exposed to 6C under the exact same conditions as those
previously reported [10], but injected with T3, survived to
more than 55 h and maintained a colonic temperature
which was either similar or at a maximum 1C lower than
that of the cold-exposed WT mice injected with T3
(Fig. 1). The body temperature of the cold-exposed b-less
mice treated with T3 was mostly equivalent to that of cold-
exposed WT mice without T3 treatment [10].
In order to test if T3 could act by itself, in the absence of
b-adrenergic signalling, on BAT UCP1 expression, the
amount of UCP1 protein was measured in the BAT mito-
chondria of WT or b-less mice exposed to 6C for 48 h
with or without T3 treatment. The amount of UCP1 protein
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Fig. 1 Thermoregulation during exposure to 6C of WT (r) and b-
less (j) 3-month-old female mice injected intraperitoneally with
0.5 lg/g of body weight of T3 at the times indicated in ‘‘Materials
and methods’’. The results are the colonic temperatures expressed in
C at various periods of cold exposure. They are the means ± SEM,
n = 5
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(expressed per 50 lg of mitochondria proteins) was
decreased by 18% in the b-less as compared to the WT
mouse BAT. Cold exposure increased 2.3-fold the amount
of UCP1 protein in the WT mouse BAT, whereas it had no
effect in the b-less mouse BAT. As a result, UCP1 protein
level was higher (3.3-fold) in WT than in b-less cold-
exposed mouse BAT. T3 treatment decreased by 63% the
amount of UCP1 protein in the WT mouse but had no
effect in the b-less mouse BAT (Fig. 2).
It was interesting to test the hypothesis that T3 treatment
might act via an effect on the skeletal muscle. We observed
that, in the muscle of b-less mice exposed to 6C for 12 h,
T3 treatment increased the amount of UCP3 protein
(expressed per 50 lg of muscle homogenate proteins) 1.3-
fold (Fig. 3).
UCP3KO mice
To test the hypothesis that the T3-induced increase in
muscle UCP3 expression could be a determinant of the
effect of T3 on thermogenesis, an UCP3KO model was
used.
UCP3KO mice were fertile and their progeny displayed
a classical sex ratio of 50% males and 50% females. When
UCP3KO mice were crossbred with WT mice, the allele
distribution revealed a Mendelian-type transmission.
To analyse our model, we performed a phenotyping
centred on energy metabolism of 2-month-old female WT
and UCP3KO mice fed a standard laboratory chow diet.
The food intake and body weight were similar in UCP3KO
and WT mice (Fig. 4a, b). Circulating free fatty acids,
leptin, glucose and insulin levels, measured after a 2 h of
fast, were also similar in UCP3KO and WT mice.
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Fig. 2 Western blot quantification of the UCP1 protein/50 lg of BAT
mitochondria of WT and b-less 3-month-old female mice, maintained
at 24C or exposed to 6C for 48 h. The cold-exposed mice were
injected or not intraperitoneally with 0.5 lg/g of body weight of T3
(?T3) at the times indicated in ‘‘Materials and methods’’. The results
are expressed in arbitrary units. They are the means ± SEM, n = 3–6.
*** P \ 0.001 vs. respective control mice at 24C or at 6C without
T3. ?? P \ 0.02 and ??? P \ 0.001 between genotypes
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Fig. 3 Western blot quantification of the UCP3 protein/50 lg of
muscle homogenate of b-less 3-month-old female mice, exposed to
6C for 12 h. The cold-exposed mice were injected or not intraper-
itoneally with 0.5 lg/g of body weight of T3 at the times indicated in
‘‘Materials and methods’’. The results are expressed in arbitrary units.
They are the means ± SEM, n = 6. ** P \ 0.02 vs. controls without
T3 (wo T3)
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Fig. 4 (a) Food intake and (b) body weight of 2-month-old female
WT and UCP3KO mice before and after implantation of a minipump
delivering T3 (basal and ? T3, respectively). The values are the
means ± SEM of 5–6 WT and UCP3KO mice and are expressed as
gram per day (g/day) of food intake and as gram (g) of body weight
before and during the 3 days of T3 treatment. * P \ 0.05 vs.
respective basal values
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Our UCP3KO mice therefore did not seem to display
any gross energy metabolism phenotypic differences with
their WT counterparts. To test our hypothesis of a privi-
leged relationship between T3 and UCP3 activity, we
performed a series of experiments in which circulating T3
level, body weight, food intake and energy expenditure
were measured in 2-month-old mice treated or not with T3.
The basal oxygen consumption of 2-month-old WT and
UCP3KO mice was measured for 24 h, using an indirect
calorimetry chamber. Then, T3 was administered by an
osmotic minipump implanted subcutaneously on the back
of the mice and delivering 6 lg of T3 in NaCl 0.9% per
day. The T3-induced changes in metabolic rate were
monitored during the three consecutive days in the indirect
calorimetry chambers. Parallel experiments were per-
formed in WT mice in which osmotic minipumps deliv-
ering vehicle (NaCl 0.9%) alone were implanted. No effect
of the implantation was observed on body weight, food
intake or oxygen consumption (results not shown). The
control mice were chosen as the naive animals before T3
minipump implantation. This allowed direct comparisons
in the same animal in two consecutive periods of time. The
basal levels of circulating T3 were similar in WT and
UCP3KO mice. After 3 days of T3 treatment, the levels of
circulating T3 increased significantly (n = 4–5, P \ 0.01)
4.8- and 6.2-fold, reaching 6.2 ± 0.9 and 7.9 ± 0.3 nmol/l
in WT and UCP3KO mice, respectively, no difference
being observed between genotypes. The increase in T3
during the treatment confirmed a normal delivery of the
hormone in vivo by the minipump.
During the 3 days of T3 treatment, the mean food intake
increased 1.4- and 1.3-fold in WT and UCP3KO mice,
respectively, but there was no difference between genotypes
(Fig. 4a). An increase in food intake by T3 has already been
reported [26]. This result was therefore expected and sug-
gests that the infused hormone was physiologically active.
The mouse body weights were similar between genotypes
and before and after the T3 treatment (Fig. 4b). An increase
in food intake with no resultant increase in body weight
suggests an increase in energy expenditure.
Figure 5 shows representative oxygen consumption
curves of WT and UCP3KO mice during a period of 14 h,
encompassing the dark period as well as of WT and
UCP3KO mice during the same period, between the second
and third day after the beginning of the T3 treatment. It can
be seen that T3 treatment increases oxygen consumption
rate, the peak values of the WT mice being systematically
higher during the dark period than those of the UCP3KO
mice. The resting oxygen consumption was calculated as
the mean of the five lowest values of individual oxygen
consumption during the light period. These values, which
measured the oxygen consumption when the mice were at
rest, can be considered as the basal metabolic rate. Fig-
ure 6a shows the basal metabolic rate of WT and UCP3KO
mice during the light period of the day before the T3
treatment and of the second day of treatment. Before the T3
treatment, the basal metabolic rates were similar in WT and
UCP3KO mice. T3 increased the basal metabolic rates of
WT mice 1.12-fold. It also increased this parameter, but
not significantly, in UCP3KO mice (paired t-test). During
T3 treatment, the basal metabolic rates of WT and
UCP3KO mice were similar. The dark period, between
7.00 p.m. and 7.00 a.m., is that during which the mice were
the most active at consuming food. For this period, we
expressed the oxygen consumption values as areas under
the curves (AUC). Figure 6b shows the AUC values before
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Fig. 5 Oxygen consumption of
2-month-old female WT and
UCP3KO mice before and after
implantation of the minipump
delivering T3 (basal and T3,
respectively). The mice were
caged individually at 24C with
light from 7.00 a.m. to
7.00 p.m. and oxygen
consumption was measured by
indirect calorimetry during a
period of 14 h encompassing
the dark period between the
second and third day of
treatment. Values were
collected every 12 min. They
are the means of five WT and
six UCP3KO mice and are
expressed as ml of oxygen
consumed per kg0.75 of body
weight in 1 h. SEM bars are not
shown for more clarity
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T3 treatment and during the dark period between the sec-
ond and third day of treatment. Before T3 treatment, the
mean oxygen consumption AUCs were similar in WT and
UCP3KO mice. T3 increased the mean oxygen consump-
tion AUCs of WT and UCP3KO mice 1.18- and 1.12-fold,
respectively. The difference between the T3 effects was not
significant (paired t-test). However, the absolute mean
oxygen consumption value of the T3-treated WT mice was
significantly higher by 6% than that of the T3-treated
UCP3KO mice (unpaired t-test). The VCO2 and the
respiratory quotient were measured and no difference could
be detected between the two genotypes under both basal
and T3-stimulated conditions.
Neither the lack of UCP3 nor our 3-day T3 treatment
modified BAT UCP1 mRNA expression (results not
shown).
Discussion
This study shows that the administration of T3 rescues the
dramatic cold intolerance of b-less mice, suggesting that
T3 has effects independent of the sympathetic nervous
system. These effects and the possible mechanisms of the
rescue have been analyzed. Cold exposure induces, among
others, an increase in BAT mitochondrial protein content as
well as in UCP1 expression and activity, which is mediated
by the sympathetic nervous system [2]. Our results show
only a slight reduction in the level of BAT UCP1 protein in
b-less as compared to WT mice maintained at 24C. This
suggests that, at this temperature slightly below thermo-
neutrality, an adrenergic signalling pathway other than the
b-, potentially the a-adrenergic system, compensates for
the lack of b-adrenoceptors. Our results also confirm pre-
vious observations showing that the cold-induced increase
in BAT UCP1 protein is blunted by the absence of
b-adrenoceptors [10, 11] suggesting that, under an acute
cold-stress condition, the compensation system becomes
insufficient. Unexpectedly, T3 administration decreased the
level of UCP1 protein in cold-exposed WT mouse BAT. It
has been reported, in rats treated with thyroxine, that the
induced rise in obligatory thermogenesis reduces the
demand for non-shivering thermogenesis [27]. In this
study, T3 administration, by increasing obligatory ther-
mogenesis, induced the observed decrease in WT BAT
UCP1 expression. Finally, T3 treatment had no effect on
the amount of UCP1 protein in the b-less mouse BAT.
Altogether, these results suggest that the effects of T3 on
WT and on b-less mouse thermogenesis are not mediated
by an effect of the hormone on BAT UCP1 expression.
T3 has been shown to induce an increase in muscle
UCP3 expression in WT rodents [22]. These data are cor-
roborated by our observation that T3 increases the level of
UCP3 protein expression in cold-exposed b-less mice.
Since UCP3 expression is increased by T3, it might as a
consequence be involved in the rescue of the dramatic cold
intolerance of b-less mice by T3. This hypothesis, how-
ever, is in contradiction with the findings that challenge a
role of UCP3 in adaptative thermogenesis [28]. However,
the hypothesis that UCP3 is a target of the thermogenic
effect of T3 was supported by the study of de Lange et al.
[22] showing that the increase in muscle UCP3 expression
by T3 was paralleled by an increase in metabolic rate in
WT rodents. To support unequivocally this hypothesis, the
use of our UCP3KO mouse model seemed most
appropriate.
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Fig. 6 a Basal metabolic rate of 2-month-old female WT and
UCP3KO mice before and after implantation of the minipump
delivering T3 (basal and ? T3, respectively). The values are those
obtained during the light period (7.00 a.m. to 10.00 a.m. and
3.00 p.m. to 7.00 p.m.) of the day before the treatment and of the
second day of treatment, respectively. They are the means ± SEM of
minimal oxygen consumption values of five WT and six UCP3KO
mice (five data per mouse) and are expressed as ml of oxygen
consumed per kg0.75 of body weight in 1 h. * P \ 0.05 vs. basal
value. b Oxygen consumption of 2-month-old female WT and
UCP3KO mice before and after implantation of the minipump
delivering T3 (basal and ? T3, respectively). The values are those
obtained during the dark period (7.00 p.m. to 7.00 a.m.) between the
second and third day of treatment. They are the means ± SEM of the
areas under the curve (AUC) of five WT and six UCP3KO mice and
are expressed as ml of oxygen consumed per kg0.75 of body weight
per hour. * P \ 0.05 and *** P \ 0.001 vs. respective control mice.
? P \ 0.05 between genotypes
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The metabolic phenotyping of our UCP3KO mice con-
firmed previous studies, on similar models, showing that
the lack of UCP3 does not modify food intake and body
weight [13–15]. It also confirmed that the lack of UCP3
does not affect the levels of circulating glucose, insulin,
FFA [14] and leptin [13]. It is noteworthy that a slight
decrease in circulating glucose and FFA was reported by
Gong et al. [13] which was observed neither in our study
nor in that of Vidal-Puig et al. [14].
Indirect calorimetry measurements have been performed
in the three UCP3KO models and it was unanimously
reported that the lack of UCP3 does not affect oxygen
consumption, either during the light or the dark period [13–
15]. In one of the UCP3KO models, indirect calorimetry
detected an increase in the respiratory quotient, indicating
impaired fatty acid oxidation [15].
Gong et al. [13] compared the effects of T3 on the
oxygen consumption of WT and UCP3KO mice. Their T3
treatment consisted in an injection of 1 mg/kg per day for
4 days. After the fourth injection, indirect calorimetry was
performed and T3 was found to stimulate oxygen con-
sumption during the dark period similarly in WT and
UCP3KO mice. In this study, the protocol chosen for T3
administration was more physiological as far as the mode
of administration and the dosages were concerned. As a
consequence, the T3-induced increases in oxygen con-
sumption were small and subtle inter-genotype differences
in response to T3 could be revealed. This trend was con-
firmed during the dark period where the difference between
the two genotypes became significant, suggesting that
UCP3 is needed for a total effect of T3. The fact that the
difference between genotypes in T3-stimulated mice is
only observed during the dark period suggests that UCP3
might become uncoupling during metabolically active
periods combining physical activity and high fuel disposal.
Under our experimental conditions, the T3-induced
increase in energy expenditure in both WT and UCP3KO
mice probably compensated for the increase in food intake
and thus prevented an increase in body weight. The differ-
ence in energy expenditure between WT and UCP3KO mice
is probably not sufficient to result in differences in body
weight between the two genotypes. It is not possible to
quantify the part played by UCP3 in the rescue by T3 of the
b-less mouse cold intolerance. An elegant way to answer this
question would be to generate a b-less-UCP3KO mouse.
It has already been reported that UCP3KO mice do not
display compensatory up-regulations of UCP1 mRNA in
their BAT and of UCP2 mRNA in their skeletal muscle
[14]. The same absence of UCP1 compensation was
observed in our UCP3KO mice. Therefore, the inter-
genotype difference in oxygen consumption observed in
this study upon T3 treatment cannot be ascribed to changes
in BAT UCP1 expression. It has also been reported that the
lack of UCP3 does not modify the physical activity [13].
Therefore, the inter-genotype difference in oxygen con-
sumption upon T3 treatment should not be ascribed to
changes in physical activity.
Altogether, our indirect calorimetry studies are in line
with the idea that UCP3 may be involved in the rescue of
the dramatic cold intolerance of b-less mice by T3. It
should be kept in mind that the effects of T3 in b-less mice
might also be mediated by effects of the hormone on futile
cycles and shivering.
Altogether, our results suggest that UCP3 is involved in
a non-negligible part of the effect of T3 on oxygen con-
sumption and, as a consequence, that UCP3 might be
involved in the correction by T3 of the dramatic cold
intolerance of the b-less mice. These results reactivate the
idea that UCP3 might play a role in the control of energy
balance.
Materials and methods
Animals
The mice were treated in accordance with our institutional
guidelines and all procedures used were approved by the
Office Ve´te´rinaire Cantonal (Geneva, Switzerland). They
were maintained at 24 ± 1C or at 6 ± 1C for the cold-
exposure experiments on a 12 h/12 h light cycle (7.00 a.m.
to 7.00 p.m.) with free access to water and standard labo-
ratory chow diet (Nordos, Cergy, France). Mice were
housed individually 10 days before and throughout the
experiments. In UCP3KO mouse experiments, food intake
was measured every third day and corrected for spillage. At
the end of the experiments, the mice were killed by cervical
dislocation.
b-less mice
b-less and WT strains were obtained by inter-crossing our
b3-KO mice [29] and b1/b2-KO mice [30], kindly provided
by Dr. B.K. Kobilka (Howard Hughes Medical Institute,
Stanford, CA, USA). b1
?/-b2
?/-b3
?/- offsprings were cros-
sed to generate b1
?/?b2
?/?b3
?/? (WT) and b1
-/-b2
-/-b3
-/- (b-
less) mice, from which were established WT and b-less
colonies on the same, mixed 129 Sv/ev, 129 SvJ, FVB/N,
C57BL/6J and DBA/2 genetic background. Genotypes
were determined by Southern blot [10]. Studies were per-
formed on 3-month-old female mice.
UCP3KO mice
As shown in Fig. 7a, the targeting vector was constructed
by deleting 6 kb of the Ucp3 gene consisting in a part of
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exon II, from the ATG start codon and downstream, and in
the totality of exons III and IV. The deleted fragment was
replaced by a neomycin-resistance gene driven by a PGK
promoter (PGK-Neo) surrounded by two loxP sequences.
These loxP sequences could be used to delete the neomycin-
resistance gene. The UCP3KO mice were generated using
the technique described by Revelli et al. [29]. We chose to
generate the mice in the C57BL/6J obesity-prone genetic
background. Thus, C57BL/6J mouse embryonic stem cells
were electroporated with the targeting vector and homolo-
gous recombinant clones were injected into C57BL/6J
blastocysts. Genotypes were determined by Southern blot.
Genomic DNA was isolated from the mouse tail by sodium
dodecylsulphate/proteinase K digestion followed by salt
precipitation. The DNA was digested with Sac1 and ana-
lysed using a standard Southern blot technique. The UCP3
probe used recognized a part of the 30-untranslated region of
the Ucp3 gene absent from the targeting vector. It therefore
allowed distinguishing between random insertion and
homologous recombination events. The probe was labelled
by random priming with [a-32P]-dCTP to a specific activity
of approximately 1 9 109 dpm/lg of DNA. Hybridizations
were performed using QuickhybTM solution as previously
described [31]. Blots were exposed at -80C to Hyperfilm
ECL films. Total gastrocnemius muscle RNA was isolated
by the method of Chomczynski and Sacchi [32], and UCP3
mRNA was quantified by Northern blot, using mouse UCP3
and human b-actin full-length cDNA probes as previously
described [33]. Gastrocnemius muscle mitochondria were
prepared as previously described [34] and the pellet sus-
pended in 400 ll of distilled water. The Western blots were
performed as described below.
Body temperature and T3 treatment
The colonic temperature was measured as an index of body
temperature in mice accustomed to handling to minimize
any artefactual increase in body temperature. A lubricated
Fig. 7 a Schematic representation of the strategy used for UCP3 gene
disruption. Wild-type UCP3 gene, targeting vector (UCP3KO con-
struct) and recombinant allele are shown. The targeting vector was
constructed by deleting 6 kb of the Ucp3 gene consisting in a part of
exon II, from the ATG start codon and downstream, and in the totality
of exons III and IV. The deleted fragment was replaced by a neomycin-
resistance gene driven by a PGK promoter (PGK-Neo) surrounded by
two loxP sequences (black triangles). These loxP sequences could be
used to delete the neomycin-resistance gene. C57BL/6J mouse
embryonic stem cells were electroporated with the targeting vector
and homologous recombinant alleles were obtained. b Genotyping of
the UCP3KO mice by Southern blot. The Sac1-digested DNAs of the
WT and UCP3KO mice were analysed by Southern blot, using an
UCP3 probe. The Sac1 digestion fragment of the WT allele displayed
the expected size of 12 kb, whereas that of the truncated allele, in
which the deleted 6 kb fragment was replaced by the 4 kb neomycin-
resistance gene, displayed the expected size of 10 kb. c Northern blot
detection of an UCP3 RNA signal in skeletal muscle mRNA of wild-
type (?/?) and UCP3KO mice (-/-). The signal observed in the ?/?
lane is replaced in the -/- lane by a smaller one. This short
messenger, that lacks the start codon, was unable to translate into a
protein, as shown in the Western blot. d Western blot detection of
UCP3 protein in skeletal muscle mitochondria of wild type (?/?)
mice. No UCP3 protein can be detected in UCP3KO (-/-) mice
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digital probe was inserted 2 cm into the colon and held
until a steady peak temperature was measured (Ellab
thermometer, Copenhagen). For T3 treatment, 15 lg of the
hormone was dissolved in 50 ll of a solution containing
NaCl 0.9% and mouse serum 1% and injected intraperi-
toneally immediately before cold exposure, and then three
times at intervals of 12 h (8.00 a.m. to 8.00 p.m.). Each
dose of T3 injected/g of body weight was between 50% and
2.5-fold doses previously used in the rat [3, 27].
Blood thyroid hormones
Serum was obtained from tail bleeds. T4 and T3 were
measured by radioimmunoassay (Buhlmann, Basel,
Switzerland).
Western blots
BAT mitochondria were prepared as previously described
[34]. Gastrocnemius muscle homogenate was prepared in
five volumes (ml/g) of RIPA buffer (150 mM NaCl, 1%
Nonidet P-40, 0.5% Na deoxycholate, 0.1% SDS, 1:200
protease inhibitor cocktail, Sigma Chemical Co, St Louis,
MI and 50 mM Tris/HCL pH 8.0). Protein concentrations
were measured according to Bradford [35] using the Bio-
Rad protein assay, with bovine serum albumin as a stan-
dard. Exactly 50 lg of proteins were dried under vacuum
and, after dissolution in 10 ll of a loading buffer con-
taining 20% glycerol, 6% SDS, 0.02% bromophenol blue
and 15% 2-mercaptoethanol in 0.25 M Tris/HCL pH 6.8,
loaded on the gel. Western blots were performed using a
sheep polyclonal primary anti-UCP1 antibody generously
provided by Dr. D. Ricquier (Meudon, France) and a rabbit
anti-human UCP3 antibody, CabrX (Research Diagnostics,
Inc, San Antonio, TX). The signals were detected by
chemiluminescence using a standard ECL kit and devel-
oped on a Hyperfilm ECL film.
Indirect calorimetry
Oxygen consumption of WT and UCP3KO mice was
measured using the OXYMAX system 4.93 (Columbus
Instruments, Columbus, OH). Mice were caged individually
in four 1-l chambers at 24C with free access to food and
water. Settling and measuring times were both of 120 s.
Room air served as reference air. The resting oxygen con-
sumption was estimated as the mean of the five lowest
values of individual oxygen consumption during the light
period. Total oxygen consumption was calculated as the
area under the curve of the oxygen consumption for the dark
period. T3 was dissolved as described for T4 by Cettour-
Rose et al. [36]. Six WT and five UCP3KO 2-month-old
female mice were placed in the indirect calorimetry
chamber for 24 h and their oxygen consumption was mea-
sured. Then, osmotic minipumps (Alzet, model 2001,
Cupertino, Canada) delivering 6 lg of T3 in 90 ll, or the
same volume of the vehicle (NaCl 0.9%) per day for 3 days,
were implanted subcutaneously on the back of the mice
under isofluorane (Abbott Laboratories, Abbott Park, IL)
anaesthesia. Animals were reinstalled in the chamber and
the oxygen consumption was measured during 3 days. At
the end of the experiment, the mice were killed by cervical
dislocation and the BAT were dissected and immediately
frozen in liquid nitrogen. At the same time, blood samples
were collected and 100 ll of serum was used for total T3
quantification.
Statistical analyses
Significance was evaluated using unpaired or paired Stu-
dent’s t-tests and the computer software STATISTIX,
version 4.0 (Analytical Software, St. Paul, MN).
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